Abstracts tagged "Osteoarthritis"

Abstract Number: 1974 • ACR Convergence 2024
The Impact of Concomitant Shoulder Osteoarthritis in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, David Kane⁴ and Richard Conway⁵, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁵Trinity College Dublin, Dublin, Ireland
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the shoulder and pelvic girdle. In the majority of centres, baseline shoulder radiograph forms part…
Abstract Number: 2100 • ACR Convergence 2024
Exploring the Association Between Basketball Participation and Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Ahmed Alderazi¹, Grace Lo², Jeffrey Driban³, Timothy McAlindon⁴, Bonny Rockette-Wagner⁵, Charles Eaton⁶, Marc Hochberg⁷, Kent Kwoh⁸ and Michael Nevitt⁹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine / MEDVAMC, Houston, TX, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts Chan Medical School, Worcester, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Memorial Hospital of Rhode Island, Pawtucket, RI, ⁷University of Maryland School of Medicine, Cambridge, MD, ⁸University of Arizona, Tucson, AZ, ⁹University of California, San Francisco, San Francisco, CA
Background/Purpose: Basketball is a globally popular sport, but research on the relationship between basketball and knee osteoarthritis (OA) is lacking. This study aims to assess…
Abstract Number: 2656 • ACR Convergence 2024
Short-Term Effectiveness of a Walk with Ease Program Delivered by Telephone on Arthritis-Related Symptoms, Function, and Physical Activity
Christine Pellegrini, Sara Wilcox, Yesil Kim, Katherine Devivo, Scott Jamieson, Kailyn Horn and Daniel Heidtke, University of South Carolina, Columbia, SC
Background/Purpose: Walk With Ease (WWE) is a 6-week arthritis-appropriate evidence-based physical activity program traditionally offered in a face-to-face format. However, as many populations encounter participation…
Abstract Number: 0175 • ACR Convergence 2024
Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
Jason Jakiela¹, Yvonne Golightly², Sydney Liles³, Judy Foxworth⁴ and Daniel White⁵, ¹Winston-Salem State University, Winston-Salem, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of Delaware, Elkton, MD, ⁴Winston-Salem State University, Elon, NC, ⁵University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and stair climbing difficulty is often the first-reported limitation. Previous work…
Abstract Number: 0981 • ACR Convergence 2024
The Causal Effect of Sex Hormone-related Drugs on the Risk of Osteoarthritis – A Mendelian Randomization Study
Xing Xing¹, Ziyuan Shen², Jianan Zhu³, Yining Wang², Xingzhong Jin⁴ and Guoqi Cai², ¹Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Baltimore, MD, ²Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China (People's Republic), ³Department of Biostatistics, School of Public Health, New York University, New York, NY, ⁴Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia
Background/Purpose: Osteoarthritis (OA) is a prevalent joint disorder characterized by joint pain, disability, and the loss of articular cartilage, imposing a significant burden on patients…
Abstract Number: 1189 • ACR Convergence 2024
Certain Dosages of Fasinumab Provides Superior Benefits over Placebo in Mitigating Osteoarthritis Symptoms Albeit at Increased Health Detriments: A Systematic Review and Meta-Analysis
Muhammad Sohaib Khan¹, Wania Moeen², Umm E Salma Shabbar Banatwala², Muhammad Usman², Umar Mahmood², Syed Ashad Ahmed Fatmi², Syed Muhammad Muneeb Akhtar², Hania Shahzad³, Muhammad Talal Ibrahim⁴, Nisar Ahmed⁵, Badaruddin Sahito² and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Dow University of Health Sciences, Karachi, Sindh, Pakistan, ³UC Davis Health, Sacramento, CA, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Rapido’s Clinica Familiar, Chicago, ⁶AdventHealth, Sebring, FL
Background/Purpose: Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, is currently under investigation for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis…
Abstract Number: 1205 • ACR Convergence 2024
OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?
Gillian Hawker¹, Lauren King¹, Jean Liew², Quike Wang³, Armaghan Mahmoudian⁴, Nuria Jansen⁵, Ian Stanaitis⁶, Jos Runhaar⁵, Tom Appleton⁷, Aleksandra Turkiewicz⁸, Martin Englund⁹, Stefan Lohmander⁹, Ida Kristin Haugen¹⁰ and Tuhina Neogi¹¹, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, ¹University of Toronto, Toronto, ON, Canada, ²Boston University, Boston, MA, ³Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), ⁴University of West Florida, Pensacola, FL, ⁵Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Women's College Hospital, Toronto, ON, Canada, ⁷The University of Western Ontario, London, ON, Canada, ⁸,Lund University, Lund, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). In individuals with undiagnosed knee…
Abstract Number: 1655 • ACR Convergence 2024
Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Target for Osteoarthritis
UXIA NOGUEIRA-RECALDE¹, christian García-Dominguez², Patricia Diaz-Rodriguez³, francisco J Blanco⁴, eduardo Dominguez³ and BEATRIZ CARAMES¹, ¹INSTITUTO DE INVESTIGACION BIOMEDICA DE A CORUÑA (INIBIC), A Coruña, Spain, ²IINSTITUTO DE INVESTIGACION BIOMEDICA DE A CORUÑA (INIBIC), A Coruña, Spain, ³UNIVERSIDAD DE SANTIAGO DE COMPOSTELA, SANTIAGO DE COMPOSTELA, Spain, ⁴INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Disease-modifying drugs (DMOADs) to prevent Osteoarthritis (OA) are an urgent clinical need. Recent advances demonstrated that targeting senescence and autophagy in chondrocytes might be…
Abstract Number: 2003 • ACR Convergence 2024
Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival
Laura Cappelli¹, Shadpour Demehri¹, Joseph Murray¹, Julie Brahmer¹, Elena Ghotbi¹, Durrant Barasa¹, Clifton Bingham² and Ami Shah³, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Rheumatologists are increasingly called upon to manage patients with inflammatory arthritis (IA) due to immune checkpoint inhibitor (ICI) therapy. The pathogenesis of ICI-IA is…
Abstract Number: 2101 • ACR Convergence 2024
Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis
Hannah Brubeck¹, David Azizi², Sarah Wetzel², Marianna Olave², Rachel Gillcrist³, Bridget Kramer⁴, Bibiana Ateh⁵, Daniel White⁶, Carla Scanzello⁷, Tuhina Neogi⁸, Alexis Ogdie⁹, Bryant England⁴, Mercedes Quinones¹⁰, Katherine Wysham¹¹ and Joshua Baker⁷, ¹VA Puget Sound Health Care System, Seattle, WA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Washington DC VA Medical Center, Washington, DC, ⁶University of Delaware, Newark, DE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰Washington DC VA Medical Center, Bethesda, MD, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Despite strong recommendations for physical activity in knee osteoarthritis (KOA) clinical practice guidelines, only a small fraction of those with KOA meet guidelines for…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: L04 • ACR Convergence 2023
EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
James Helliwell¹, Amanda Malone¹, Mark Kowalski², Asger Reinstrup Bihlet³, Claire Miller⁴, Alejandro Castillo Mondragon⁵, Yanqi Li⁶, Christine Dobek⁷, Vik Peck¹, Mike Wilmink⁸ and Lee Simon⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²Eupraxia Pharmaceuticals, Winchester, VA, ³NBCD A/S, Soeborg, Denmark, ⁴NBCD A/S, Copenhagen, Denmark, ⁵NBCD, Copenhagen, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷Eupraxia Pharmaceuticals, Edmonton, AB, Canada, ⁸OrthoArizona, Phoenix, AZ, ⁹SDG LLC, Cambridge, MA
Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…
Abstract Number: L05 • ACR Convergence 2023
DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis
Guoqi Cai¹, Graeme Jones², Flavia Cicuttini³, Anita Wluka³, Yuanyuan Wang³, Catherine Hill⁴, Helen Keen⁵, Benny Antony², barbara de Graaff², Michael Thompson², Tania Winzenberg², Kathy Buttigieg², Petr Otahal² and Dawn Aitken², ¹School of Public Health, Anhui Medical University, Hefei, China, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Monash University, Melbourne, Australia, ⁴The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁵Fiona Stanley Hospital, Murdoch, Australia
Background/Purpose: There is an unmet need for treatments of knee OA. Diacerein is recommended for alleviating pain in OA patients for its anti-inflammatory effect by…
Abstract Number: 0153 • ACR Convergence 2023
Diminished Vibration Perception and Greater Pressure Pain Sensitivity Are Associated with Worse Knee Osteoarthritis Outcomes Across Sex and Race
Chris Lane¹, Louise Thoma², Carolina Alvarez³, Deborah Givens⁴, Amanda Nelson⁴, Adam Goode⁵, Kharma Foucher⁶ and Yvonne Golightly⁷, ¹UNC Chapel Hill, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Miami, FL, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Durham, NC, ⁶University of Illinois at Chicago, Chicago, IL, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Sex and race differences have been observed in clinical outcomes such as patient-reported pain and function in adults with knee OA. However, few studies…

« Previous Page
1
…
7
8
9
10
11
…
63
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].